Scleroderma

Foreword -- Introduction - Section One: The pathogenesis and pathology of scleroderma; risk factors and epidemiology - Epidemiology and risk factors- Vascular - Immunity and the genesis of autoantibodies - Innate immunity -- Fibrosis -- Genetics - Animal models of scleroderma - Biomarkers and gene expression profiling for understanding pathogenesis and use in clinical trials and patient management - Metrics and outcome measures - Section Two: Clinical features of scleroderma - Recognizing disease subsets - Autoantibodies in diagnosis, disease classification and patient management - Lung involvement: diagnosis, differential diagnosis and monitoring - CT scanning - Lung involvement: management - Pulmonary hypertension: evaluation - Pulmonary hypertension: management and monitoring - Gastrointestinal involvement: esophagus and GAVE - Gastrointestinal involvement: large bowel and - Renal crisis and other forms of renal involvement -- Raynaud phenomenon - Cardiac involvement: evaluation and management - Other vascular complications - Muscle involvement - Joint involvement, carpal tunnel syndrome -- Skin features, calcinosis. Evaluation and management - Scleroderma and pregnancy - Impotence, Erectile dysfunction - Scleroderma in children -- Localized forms of scleroderma - Nephrogenic fibrosing syndromes - Differential diagnosis of scleroderma - Section three: management - Immunomodulatory therapies -- Bone marrow Tx - Stem cell therapies - Novel disease-modifying therapies -- Physical and occupational therapy - Psychological aspects - Integrative and holistic approaches; diet and alternative therapies